Last reviewed · How we verify
NCT07057713
Total Arterial vs. Mixed Grafting in Left Coronary CABG
NA trial testing Total Arterial Grafting in Coronary Artery Disease in 400 participants. Not yet recruiting.
1 August 2026
Quick facts
| Lead sponsor | Second Hospital of Jilin University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 400 |
| Start date | 1 August 2025 |
| Primary completion | 1 August 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Total Arterial Grafting
- Conventional Mixed Grafting
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
- Coronary Artery Bypass Grafting — all drugs for Coronary Artery Bypass Grafting →
- Arterial Graft — all drugs for Arterial Graft →
- Graft Patency — all drugs for Graft Patency →
Sponsor
Second Hospital of Jilin University
Who can join
Adults 18 to 80, any sex, with Coronary Artery Disease or Coronary Artery Bypass Grafting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, randomized, double-blind controlled trial comparing the clinical efficacy of total arterial grafting (internal thoracic artery and radial artery) versus conventional mixed grafting (internal thoracic artery and great saphenous vein) in the left coronary artery system during coronary artery bypass grafting (CABG). A total of 400 patients undergoing elective CABG at the Second Hospital of Jilin University will be enrolled and randomized into two groups. The primary endpoint is graft patency at 12 months postoperatively, evaluated by coronary angiography or CT angiography. Secondary outcomes include perioperative complications, major adverse cardiovascular events (MACE), and long-term clinical prognosis. The study aims to provide evidence-based guidance on optimal graft selection in CABG.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07057713
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Second Hospital of Jilin University trials
Trials by the same sponsor.
- NCT07272655 — AAR/AAR+HAR vs AAR+TAR+FET for Type A Aortic Intramural Hematoma · NA · not yet recruiting
- NCT06787651 — Comparison of RIMA-SVG and Ao-SVG Techniques in Coronary Artery Bypass Grafting · NA · active not recruiting
- NCT06218160 — The Addition of Hydromorphone to Local Anesthetics for the Repair of Inguinal Hernias in Elderly Patients · NA · completed
- NCT06205199 — Analgesic Effect of Ropivacaine Combined With Hydromorphone for CSEA After Total Knee Arthroplasty · NA · completed
- NCT06240858 — Clinical Study of Self-gripping Mesh in TAPP Versus Lichtenstein Hernia Repair · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07057713 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Hospital of Jilin University
- Last refreshed: 10 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07057713.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing